American Society for Microbiology, Infection and Immunity, 9(86), 2018
DOI: 10.1128/iai.00423-18
Full text: Unavailable
The success of polysaccharide conjugate vaccines represents a major advance in the prevention of pneumococcal disease, but the power of these vaccines is limited by partial spectrum of coverage and high cost. Vaccines using immunoprotective proteins are a promising alternative type of pneumococcal vaccines.